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Resistance to Schistosoma mansoni infection has been correlated with IgE responses to the adult worm.
Molecular targets of this response are gaining interest as markers of immunity and as indicators of
allergenic properties. Few protein families contain IgE antigens (allergens) and one of the most highly
represented are the tropomyosins. Alternative splicing generates numerous tropomyosin isoforms, which
in parasites is likely to induce a range of anti-tropomyosin responses in the host. Here we examine
human IgE and the counteracting IgG4 responses to splice variants of S. mansoni tropomyosin (SmTpm).
It was possible to show life-cycle transcription proﬁles for 12 of 20 predicted splice variants from the four
SmTpm genes. We expressed recombinant protein of four variants of TpmII (TpmII.4, 8, 3 and 7) with
considerable differences in sequence. TpmII.4 and 8 were muscle, and TpmII.3 and 7 non-muscle, types.
IgE and IgG4 responses to all four proteins were measured in a population of 228 infected boys and men
(7–76 years) from a region of Uganda endemic for S. mansoni. Levels of these antibodies were not
dependent on age and did not change following anthelminthic treatment. IgE to TpmII.3 was common
in the cohort (>60%) and IgG4 to TpmII.3 less so (33%). IgE to TpmII.7 was rare (6.5%), but IgG4 to TpmII.7
was more common (49%). In regression analysis, a detectable IgE response to TpmII.3 was associated with
reduced re-infection 2 years after treatment and an IgG4 response to TpmII.7 with increased re-infection.
Different isoforms generated by alternative splicing are targeted by different components of the anti-Tpm
IgE/IgG4 response. Only some of these are associated with immunity.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Infection with Schistosoma mansoni is a serious health problem
in sub-Saharan Africa. For people living where the parasite is
endemic, repeated exposure to infectious cercariae can result in
life-long infection. Partial immunity does gradually develop and
epidemiological studies show that this is correlated with an IgE re-
sponse to the worm (Rihet et al., 1991; Dunne et al., 1992, 1997;
Pinot de Moira et al., 2010; Fitzsimmons et al., 2012b). In fact, par-
asite-speciﬁc IgE has been associated with protection in a wide
range of helminth infections (Hagan et al., 1991; Dunne et al.,
1992; Faulkner et al., 2002; Bethony et al., 2005; Capron et al.,2005; Turner et al., 2005) leading to the widely-held belief that
IgE evolved to help counter these multicellular parasites.
IgE also plays a central role in allergy and some propose that
allergic responses are anti-parasite responses misdirected to other-
wise harmless species (Artis et al., 2012). We have suggested that
not only are the IgE-mediated processes in allergic and anti-worm
responses the same, but so are the types of molecules targeted
(Fitzsimmons and Dunne, 2009). Allergens come from a small
number of protein families (Radauer et al., 2008) and the
anti-worm IgE targets discovered thus far are all from these
families (Fitzsimmons and Dunne, 2009). For example, the EF-hand
proteins are some of most common molecular allergens (Radauer
et al., 2008) and in S. mansoni, the EF-hand-containing Tegumen-
tal-allergen-like (SmTAL) protein family are dominant IgE antigens.
IgE responses to a number of these proteins (SmTAL1, 3 and 5)
have been associated with resistance to infection (Dunne et al.,
1997; Fitzsimmons et al., 2012b).
Schistosome tropomyosin (Tpm) is another likely target for the
host IgE response. Tpm has been described as an invertebrate
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in species ranging from shellﬁsh and dust mites to the parasitic
nematode Anisakis simplex (Asturias et al., 2000; Resch et al.,
2011). The canonical view is that invertebrate Tpms sharing <55%
identity with their human homologues may cause allergy whereas
more similar (e.g. mammalian) Tpms do not (Jenkins et al., 2007).
Within any species there can be as many as 40 different Tpm
isoforms. These serve a range of functions in different tissues
(Schevzov et al., 2005), at different developmental stages and in
both muscle contraction and cytoskeletal structure/function
(Perry, 2001; Gunning et al., 2005). In vertebrates the multiple iso-
forms are achieved through extensive differential RNA splicing
(Perry, 2001) and there is evidence that this is also the case for
invertebrates (Jeong et al., 2004; Alvite and Esteves, 2009). IgE
binding has been examined for a number of allergenic Tpm pro-
teins and epitopes have been predicted (Sereda et al., 2008), but
the issue of multiple isoforms has not been addressed. Different
isoforms can vary considerably in regions of the molecule, and this
is likely to affect their antigenicity (Jeong et al., 2004).
Alternative splicing of S. mansoni Tpm (SmTpm) is predicted
from genomic studies (Berriman et al., 2009) but it is not known
whether different isoforms are expressed in different parasite
tissues or in different life stages. There is evidence from other aller-
gen-like molecules that timing and location of expression are
important in the natural history of the infection and in the host
immune response (Fitzsimmons et al., 2012a). In this report we
examine the life cycle transcription of splice variants of the four
S. mansoni genes conﬁrming transcription of 12 Tpm isoforms
and, focusing on one gene (SmTpmII), select four splice variants
with markedly different domain structures, express these as
recombinant proteins and assess IgE and IgG4 responses to the four
molecules in a cohort of infected males from a region endemic for
S. mansoni.2. Materials and methods
2.1. Parasite cDNA preparation
Total RNA from S. mansoni eggs, cercariae, cercarial heads, cerc-
arial tails, 24 h schistosomulae and 7 week adults were prepared as
previously described (Chalmers et al., 2008; Fitzsimmons et al.,
2012a). Total RNA from miracidia, 24 h sporocysts, and 99 h
sporocysts was a gift from Prof. T. Yoshino (University of
Wisconsin, USA). All parasite RNA samples were treated with
DNAse I (Roche, Germany) to remove genomic DNA contamination
and RNA integrity was assayed using an Agilent 2100 BioAnalyzer.
cDNA was synthesised from 1 lg of total RNA from each life cycle
stage using SuperScript II Reverse Transcriptase (Invitrogen, Life
Technologies, UK) and random primers, and veriﬁed to be free of
parasite genomic DNA contamination by PCR using intron-ﬂanking
primers 50-AAC TTT ACT TCG TGA TGG TGA TGA-30 and 50-ACC ACG
ACA AAA TTC TTC AAA AGT-30 from constitutively expressed
SmTAL2 (Fitzsimmons et al., 2012a).2.2. Detection of Tpm isoforms
Genes annotated as Tpms in the S. mansoni genome (Berriman
et al., 2009) on GeneDB (Sanger Institute, http://www.genedb.org/
Homepage/Smansoni). Smp_022170, Smp_031770, Smp_044010,
Smp_085290 and Smp_032490 were analysed for conserved do-
mains by BLAST searches of NCBI/GenBank databases (https://
www.ncbi.nlm.nih.gov/genbank/) and sets of primers were
designed to uniquely identify each putative alternatively spliced
isoform of every gene by PCR (Supplementary Table S1). In cases
where this was impossible, primer pairs were generated to carryout nested PCR (Supplementary Table S2). Wherever possible,
primers were designed to span introns. All PCRs in this study were
performed using Phusion Hot-Start High-Fidelity DNA Polymerase
(New England Biolabs, UK).
All reactions were performed according to the following cycling
protocol: an initial denaturation at 98 C for 30 s, 35 three-step
cycles of 98 C for 10 s, Tanneal for 20 s and 72 C for 30 s, followed
by a ﬁnal extension step at 72 C for 5 min, on a DNA Engine Tetrad
2 Peltier Thermocycle (Bio-Rad, UK). The reaction products were
then visualised by ethidium bromide (EtBr)/agarose gel electro-
phoresis. In the case of a negative result, the reaction was repeated
at annealing temperatures 2–4 C lower than the optimum, until
non-speciﬁc binding of the primers became apparent.
The primers for Smp_031770.3 (TpmII.3) were later found to
not be speciﬁc to this variant alone; they also amplify the novel
isoform Smp_031770.16 (TpmII.16) identiﬁed in this study.2.3. Cloning and sequence veriﬁcation
The coding DNA sequences (CDS) of four SmTpm II
(Smp_031770) variants, TpmII.3, 4, 7 and 8, were ampliﬁed from
cercarial cDNA using the following primers: 50-ATG AAG CTT CAG
ATA GAC CAGC-30 and 50-TTA GAT ATT TTC TAC TTC AGT AAA
CAT GG-30 for TpmII.3 (699 bp), 50-ATG GAA CAT ATT AAA AAG
AAA-30 and 50-TTA GTT TCC AGT AAG TTC TG-30 for TpmII.4
(855 bp), 50-ATG GAA GAA GCT TTA TCA G-30 and 50-TTA GTT TCC
AGT AAG TTC TG-30 for TpmII.7 (720 bp) and 50-ATG GAA CAT
ATT AAA AAG AAA-30 and 50-TTA GAA ATG CAC CTC ATC-30 for
TpmII.8 (504 bp). Amplicons were gel-puriﬁed and cloned directly
into the pJET1.2/blunt vector using the blunt-ended CloneJET PCR
cloning kit (Fermentas, UK). Recombinant plasmids were
sequenced (DNA Sequencing Facility Cambridge University,
Department of Genetics, UK). The mRNA coding sequence of
SmTpmII.3, 4, 7 and 8 were uploaded to GenBank (Accession Nos.
KC904503.1, KC904504.1 KC904505.1 and KC904506.1). While
cloning the CDS of Smp_031770.3 (TpmII.3), a novel 699 bp
isoform that was not predicted by EVM2 in the S. mansoni genome
was found. This sequence was uploaded to GenBank (KC904507.1)
as Smp_031770.16 (TpmII.16).2.4. Quantitative real-time PCR (qPCR)
Transcription levels of the common TpmII exon E and of control
gene S. mansoni RNA Polymerase II (RpII) were assayed by qPCR
using the DyNAmo Flash SYBR Green qPCR Kit (Fermentas). One
microlitre of diluted cDNA (corresponding to 5 ng of total RNA)
was used as the maximum template amount per 20 ll reaction.
Primers 50-GCT GAA GTC GCC TCA CTA CA-30 with 50-TTT CAT CAG
CAG CTT TAC TTG C-30 for TpmII exon E (121 bp) and
50-CGAAAATGATGTCAGCCTCA-30 with 50-CCGTTCTTGTGATTCCT
CGT-30 for RPII, were used at a ﬁnal concentration of 0.521 lM.
Reactions were performed according to the recommended cycling
protocol for the kit, on an Eco Real-Time PCR System (Illumina,
UK) and high-resolution melt curves were performed over a 55–
98 C range. qPCR ampliconswere cloned into pJET1.2/blunt and se-
quenced as described in Section 2.3.
Standard curves were performed over seven successive twofold
dilutions of the cercarial cDNA template in triplicate. Quantiﬁca-
tion was then performed in quadruplicate, using cDNA from each
of the life cycle stages. No-template controls were included for
each primer pair and no-primer controls were included for cDNA
from each life cycle stage. Data were analysed by the 2DCt method
(Livak and Schmittgen, 2001).
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Full CDS for TpmII variants 3, 4, 7 and 8 were ampliﬁed by PCR
from the recombinant plasmids (see Section 2.4) using speciﬁc
primers with appended restriction sites (Supplementary
Table S3). Amplicons were ligated into the pGEX-KG bacterial
expression vector between BamHI and XbaI restriction sites
(TpmII.3, 4 and 8) or between XbaI and XhoI sites (TpmII.7).
Constructs were sequenced to verify inserted sequences. GST-
TpmII fusion proteins (50 GST) were expressed in Escherichia coli,
isolated by afﬁnity chromatography on glutathione–agarose (GE
Healthcare, UK), reapplied to glutathione–agarose in PBS contain-
ing 1% Triton X-100 (Sigma–Aldrich, UK), washed with PBS and
then cleaved at 22 C for 16 h with 50 units (U) of thrombin per
mg of fusion protein to release free TpmII.3, 7 or 8 and 4 h with
30 U of thrombin per mg of fusion protein to release TpmII.4. In
each case the absence of contaminating GST was conﬁrmed by ELI-
SA using rabbit-anti-GST antisera (Sigma) and horseradish peroxi-
dase (HRP)-conjugated anti-rabbit IgG (Sigma).
2.6. Far UV circular dichroism (CD)
Secondary structure determinations were performed using an
Aviv 410 CD Spectrometer (Aviv Biomedical, USA). Antigens were
prepared at a concentration of 100–200 lg/ml in a 10 mM phos-
phate buffer, pH 7.5, containing 50 mM NaF. Thermal denaturation
of the antigens was followed at 222 nm from 25 to 95 C in 2 C
steps with an equilibration time of 30 s and an averaging time of
1 s at a 1 nm bandwidth. Renaturation was followed from 51 C
for TpmII.4, and 8, from 81 C for TpmII.3, and from 75 C for
TpmII.7. Wavelength scans were performed before and after
thermal denaturation at 25 C between 190 and 260 nm in
0.5 nm intervals with an averaging time of 1 s at a 1 nm band-
width. Baseline values were obtained by concurrent CD spectrom-
etry of buffer alone. Dynode voltages did not fall outside of the
linear range in any scans. Melting temperatures were calculated
by taking the maxima of the derivatives of thermal denaturation
curves, and percent helicity calculations were performed using
the CONTINLL analysis program (van Stokkum et al., 1990) and
the SP175 190–240 nm reference data set (Lees et al., 2006) on
the Dichroweb interface (Whitmore and Wallace, 2008).
2.7. Study cohort
IgE and IgG4 responses to TpmII variants 3, 4, 7 and 8 were
measured in a sample of adult males resident in the ﬁshing village
Musoli, located on Lake Victoria, Uganda. Full details of the study
area, population and sample selection have been described else-
where (Fitzsimmons et al., 2012a). Brieﬂy, an initial demographic
survey and parasitological screen was conducted on the entire
population of Musoli, and 228 S. mansoni-infected male inhabitants
aged 7–76 years were selected by simple random sampling
(Fitzsimmons et al., 2012a). Written informed consent was ob-
tained from all selected individualsP15 years who agreed to par-
ticipate, or from parents/guardians of selected children <15 years
giving assent. Five stool samples were taken from each individual
on different days and quantitative parasitology carried out (two
Kato-Katz thick smear slides per sample). The median infectious
burden for this cohort was 477 S. mansoni eggs per gram (epg) of
faeces (range 3–7,083 epg). Blood samples were collected from
participants before and 9 weeks after treatment with 40 mg/kg of
Praziquantel (PZQ). Of the 228 selected males, 216 donated blood
samples before treatment and 202 donated samples after
treatment. To determine the efﬁcacy of treatment and intensity
of re-infection, quantitative parasitology was also carried out at
9 weeks, 8 months and 2 years post-treatment. In line withUgandan national health policy, infected participants were treated
at 2 years (but not at 9 weeks or 8 months).
Ethical clearance for the study was obtained from the Uganda
National Council of Science and Technology (ethics committee for
Vector Control Division, Ugandan Ministry of Health).
2.8. ELISA with human plasma
Plasma IgE and IgG4 levels were measured by isotype-speciﬁc
ELISA. A coating inhibition assay was employed to estimate the sat-
urating coating concentrations for each antigen (20, 21, 15 and
6 lg/ml for TpmII.3, 4, 7 and 8) as described (Steinitz and Baraz,
2000; Fitzsimmons et al., 2012a) and 15 ll of each antigen were
dried down onto 384-well high-binding microplates (Greiner
Bio-one, UK) in 0.1 M sodium carbonate /bicarbonate buffer pH
9.6 at 22 C. The assays were then continued exactly as described
previously (Fitzsimmons et al., 2012a,b). Brieﬂy, plates were
blocked with 1% non-fat dry milk powder and incubated with plas-
ma samples diluted 1:200 (IgG4) or 1:20 (IgE). Wells were then
incubated with 0.5 lg/ml of biotinylated mouse anti-human IgE
(Clone G7-18, BD Pharmingen, UK), or IgG4 (Clone JDC-14, BD
Pharmingen), washed and then incubated with 1:3000 streptavi-
din–biotinylated HRP complex (Mast Group Ltd., UK). Finally wells
were washed again and developed with l o-phenylenediamine
substrate solution (Sigma). Plasma samples collected from 26
uninfected Europeans (after written informed consent was
obtained) were tested concurrently with each assay, and all
measurements were performed in duplicate. O.D. values were read
using a Powerwave HT microplate spectrophotometer (BioTek
Instruments Inc., UK) at 490 nm. Standard curves were generated
for every plate with the O.D. values obtained from the wells coated
with serial dilutions of human myeloma IgE (Calbiochem, USA) or
IgG4 (Sigma).
2.9. Regression analysis
The inﬂuence of post-treatment anti-TpmII antibody (IgG4 and
IgE) levels on intensity of re-infection 2 years post-treatment was
examined using linear regression analysis, with adjustment for
age. Analysis was restricted to individuals for whom treatment
was efﬁcacious, deﬁned as at least a 90% reduction in epg and
<100 epg 9 weeks post-treatment. Due to positive skew, both egg
counts (epg) and anti-TpmII antibody levels were log transformed
after the assay cut-offs were added to remove zero values. Age was
included as a categorical variable, comprising ﬁve groups of
approximately equal size. Log-likelihood ratio tests were used to
determine signiﬁcance. P < 0.05 was considered signiﬁcant.3. Results
3.1. At least 12 Tpm isoforms are present at the mRNA level in S.
mansoni
There are ﬁve genes annotated as Tpm in the S. mansoni genome:
Smp_044010 (TpmI), Smp_031770 (TpmII), Smp_022170,
Smp_085290 and Smp_032490. However, as a result of alternative
splicing it is predicted that there may be as many as 20 Tpm iso-
forms in the organism (Berriman et al., 2009). BLAST searches of
the NCBI/GenBank databases were performed to identify conserved
Tpm domains in the S.mansoni genome. Smp_032490was excluded
from further analysis as it did not map onto any known Tpm se-
quences. We then designed a nested PCR strategy to determine
which of the putative splice variants of the remaining four genes
were transcribed using cDNA prepared from seven life cycle stages
of S.mansoni aswell as isolated heads and tails of cercariae (Table 1).
Table 1
Detection of Schistosoma mansoni tropomyosin transcripts throughout the life-cycle using conventional nested PCR.
Tropomyosina Eggsb Mir. 24 h Spor. 99 h Spor. Cerc. Cerc. tails Cerc . heads 24 h Som. 7 wk Adult
TpmI.1 + + + + +
TpmI.2 + + + + + + + + +
TpmII.1
TpmII.2 + + +
TpmII.3 + + + + + + + + +
TpmII.4 + + + + + + + + +
TpmII.5 + + + + + +
TpmII.7 + + + + + + + + +
TpmII.8 + + + + + + + + +
TpmII.9 + + + + + + + + +
TpmII.10
TpmII.11
TpmII.12
TpmII.13 + + + + + + + + +
TpmII.14
TpmII.15
Smp_022170.1 + + + + + + + + +
Smp_085290.1c + + + + + + + + +
Smp_085290.3
a All genes and splice variants annotated as ‘‘tropomyosin’’ in the S. mansoni genome.
b Template cDNA was prepared from eggs, miracidia (Mir.), 24 h sporocysts (Spor.), 99 h sporocysts, whole cercariae (Cerc.), cercarial tails, cercerial heads, 24 h schisto-
somula (Som.) and 7 week (wk) mixed-sex adults.
c Isoforms of Smp_085290.1 and Smp_085290.2 differ only in one codon and were not considered separately.
Fig. 1. Exon map of Schistosoma mansoni tropomyosin (SmTpm)II. The annotated genome of S. mansoni predicts 17 exons for TpmII that are termed A–Q. Exon maps of the 14
genome-predicted splice variants and a further variant identiﬁed in the current study (TpmII.16) are shown. The common exon (E) is shaded grey. Some exons have additional
sequences when they form the 50 or 30 end of the coding region (giving sequences D0 , G0 , N0 and Q0).
384 S. Silas et al. / International Journal for Parasitology 44 (2014) 381–390Nine of the variants were detected in every life-stage. TpmI.1 and
TpmII.2 were largely restricted to the snail stages and TpmII.5
was only present in stages other than those in the snail. We were
unable to detect the predicted TpmII variants 1, 10, 11 or 12 or var-
iant 3 of Smp_085290. Overall, at least 12 isoforms from four Tpm
genes were conﬁrmed present in the S. mansoni transcriptome
(Table 1).3.2. TpmII
Since the majority of detectable Tpm isoforms arise from TpmII,
we decided to focus our study on this gene (Smp_031770) and a
detailed exon chart of S. mansoni TpmII is shown in Fig. 1. The tan-
dem duplication of exons is apparent (exons F/G, H/I, J/K, L/M, N/O
and P/Q) as is the fact that the duplicated exons, which typically
share approximately 50% identity, are spliced in a mutually exclu-
sive manner, i.e. no isoforms contain both ‘versions’ of any pair.Fig. 1 also includes TpmII.16, a splice variant (not predicted com-
putationally) that was ampliﬁed and sequenced during the cloning
of the coding region of TpmII.3 (see Section 2.3).
3.3. Quantitation of TpmII in different life stages
It was not possible to quantify individual splice variant
transcripts by qPCR. Whilst non-quantitative differentiation was
achieved using nested conventional PCR (Table 1), primers for qPCR
cannot be nested and whilst some isoforms could be distinguished
by amplifying entire coding regions in one step, the resulting ampli-
cons (500–850 bp),were too large for qPCRmethods. Itwaspossible,
however, to use qPCR on the common ‘‘E’’ exon to measure total
TpmII transcription across the different life stages. Parasitematerial
was chosen to be representative of life stages experiencedby the hu-
man host; eggs, cercariae, 24 h schistosomula and 7 week adults.
Fig. 2 shows that total transcription of TpmIIwas considerably high-
er in adult worms than in the other life stages.
Fig. 2. Quantitation of Schistosoma mansoni tropomyosin (Tpm)II transcription in
different life stages. Quantitative real-time PCR was used to measure transcription
levels of the common TpmII exon E, using cDNA prepared from the parasite material
indicated (cerc., cercariae). Transcription of the stably expressed S. mansoni RNA
polymerase II (Fitzpatrick et al., 2009; Liu et al., 2012), was measured simulta-
neously as a reference. Measurements were made in quadruplicate; shown are the
mean ± S.E.M.
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After comparing predicted amino acid sequences of all the
TpmII splice variants, four disparate examples (TpmII.3, 4, 7 and
8) were chosen in the hope of subsequently capturing a represen-
tative immunological proﬁle of the entire repertoire of splice
variants of this gene. Amino acid sequences of the four variants
are aligned in Fig. 3A. The nine N-terminal residues of TpmII.4
and TpmII.8 (MEHIKKKML) are characteristic of muscle Tpm
(Smillie, 1979). These residues are heavily conserved across spe-
cies, as they interact with actin and troponin to regulate muscle
contraction (Smillie, 1979). In contrast, non-muscle Tpms tend to
be shorter with more variable N-terminal regions (Smillie, 1979;
Côté, 1983). Together, this suggests that splice variants 4 and 8
are muscle isoforms, whilst 3 are 7 are non-muscle. Tpm 3, 4 and
7 each possess the L-K-[E A D]-A-E-x-R-A-[E T] sequence
(Fig. 3A), a heavily conserved Tpm ‘‘signature’’ motif. This is pres-
ent in both muscle and non-muscle Tpms, within a C-terminal re-
gion that is believed to enable the proper folding of the molecules
into their characteristic coiled-coil conformation (Smillie, 1979).
Finally, an immunodominant B-cell epitope [F L]-L-A-E-[E D]-A-
D-R-K-Y-D has been reported in Tpm from the nematode
Onchocerca volvulus (Jenkins et al., 1998) that coincides with an
IgE binding epitope in shrimp Tpm (Subba Rao et al., 1998). This
motif is present in all of the selected isoforms.
Fig. 3B illustrates the different protein structures generated
from these four combinations of exons. TpmII.4 is a highly repre-
sentative, 284 residue ‘‘high molecular weight’’ isoform, whilst
TpmII.8 is a truncated version, equivalent to the N-terminal half
of TpmII.4. In contrast, TpmII.7 is identical to the C-terminal 70%
of TpmII.4, but has a unique non-homologous N-terminal domain.
TpmII.3 is similar to TpmII.7 in size, but has its own unique N-ter-
minal sequence and the high degree of exon substitution in other
regions means that TpmII.3 shares less than 50% identity with
TpmII.7 overall (see Fig. 3B).
3.5. Expression and characterisation of recombinant TpmII splice
variants
The four selected splice variants were expressed in bacteria and
Fig. 4 shows SDS–PAGE analysis of the recombinant proteins. Asobserved for Tpm in other species (Jenkins et al., 1998) all four mi-
grated as greater than their predicted molecular weight values
(Fig. 4). Additional bands were sometimes seen in preparations of
TpmII.3 and TpmII.7 (e.g. Fig. 4). These were shown to be fragments
of the respective Tpm isoforms by western blotting and N-terminal
sequencing (not shown).
Even though it is widely held that conformation plays an impor-
tant role in immunological activity, recombinant antigens used for
immunological testing are rarely tested to ensure proper folding. In
this study conformation was assessed. First, TpmII isoforms were
visualised using homology modelling to predict three-dimensional
structures on the SwissModel webserver (http://swissmodel.exp-
asy.org/). The same coiled-coil alpha-helical structure was
obtained for each of the four proteins, typical of chain C crystal
structure for Tpm (PDB ID: 1c1g.C, not shown). Then, to ensure that
the secondary structure of the recombinant antigens was as pre-
dicted by the modelling, we performed CD spectroscopy on all four
puriﬁed Tpm proteins. This indicated that the recombinant
TpmII.3, 4 and 7 were indeed entirely alpha-helical, but that
TpmII.8 contained a small, more disordered helical component at
room temperature (Table 2). The thermal stability of the secondary
structure of the molecules was investigated by heating from 25 to
95 C, measuring CD at 222 nm (helix ‘signature’ wavelength) and
calculating the melting temperatures (Table 2). When the proteins
were cooled to 25 C again, they refolded almost completely
(Table 2). Wavelength scans of the antigens before and after
thermal denaturation are shown in Fig. 5. These are typical of pro-
teins with high alpha-helical content.
3.6. Anti-TpmII.3 IgE levels were associated with immunity to re-
infection
The puriﬁed recombinant antigens were used to measure TpmII
isoform-speciﬁc antibody responses in a cohort of 228 S. mansoni-
infected males. Samples were obtained before and 9 weeks after
PZQ treatment. For those that did produce a detectable response,
levels of speciﬁc IgE and IgG4 are shown in Fig. 6A and B, respec-
tively. Treatment did not affect levels of IgE or IgG4 to any of the
four isoforms tested (Fig. 6, P > 0.1). With the exception of a
post-treatment drop in the proportion of individuals with a detect-
able TpmII.7-IgG4 response (Tukey’s Honestly Signiﬁcant Differ-
ence (HSD) test; P = 0.03), prevalence of responders was also not
affected by treatment (P > 0.1). For each of the four Tpm isoforms,
IgE and IgG4 responses were often present in the same individuals.
That is, the two responses were not mutually exclusive and the less
prevalent response was detected in a subset of those with the more
prevalent response.
Fig. 7 displays prevalence of detectable anti-TpmII IgE and IgG4
responses over age. Interestingly, age does not have a strong effect
on any of the anti-TpmII responses studied. There is a trend for
TpmII.4–IgE and Tpm.8–IgE to increase with age but this does
not reach statistical signiﬁcance (Fig. 7B, D). The most prevalent
IgE response was that to TpmII.3 (Fig. 7A); over 60% (n = 146) of
the whole cohort had detectable IgE to TpmII.3, signiﬁcantly more
than to the other three isoforms (Tukey’s HSD test; P < 0.05). In
contrast, IgE to TpmII.7 was very rare (6.5% had a detectable re-
sponse, n = 14) and signiﬁcantly less prevalent than IgE to the other
three isoforms (P < 0.05). The most prevalent IgG4 response was
that to TpmII.7 (Fig. 7C), detected in 49% of the cohort (n = 112),
signiﬁcantly more than IgG4 to TpmII.3, 4 or 8 (Tukey’s HSD test;
P < 0.05).
Finally, linear regression analysis was performed to assess the
relationship between post-treatment antibody levels against the
four S. mansoni TpmII isoforms and immunity to re-infection,
allowing for age. Anti-TpmII.3 IgE levels were signiﬁcantly nega-
tively correlated with re-infection intensity 2 years post-treatment
Fig. 3. Alignment of the selected Schistosoma mansoni tropomyosin (Tpm) splice variants. The amino acid sequences of the four TpmII splice variants selected for cloning
(Tpm II.4, 8, 3 and 7) are aligned (A) with the conserved N-terminal putative ‘‘muscle interaction’’ sequence MEHIKKKML (Smillie, 1979) highlighted in black and the
sequences matching immunodominant B-cell epitope [F L]-L-A-E-[E D]-A-D-R-K-Y-D from Onchocerca volvulus (Jenkins et al., 1998) are underlined. The Tpm ‘‘signature’’
sequence L-K-[E A D]-A-E-x-R-A-[E T] is indicated by the box. Identical residues are in grey. (B) Protein structures generated by these sequences are illustrated with
contributing exons and their degree of identity to TpmII.4 are indicated. Dark grey, 100%; light grey, 25–65%; and white, <10% identity.
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signiﬁcantly positively correlated with re-infection intensity
(b = 0.14; P < 0.05, Table 4). No other associations were observed
(data not shown).4. Discussion
Alternative splicing of mRNA is an important process in
Schistosoma spp., contributing to the range of proteins required
for parasite development and interaction with the host (Verjov-
ski-Almeida and DeMarco, 2011). The current study demonstrates
that the SmTpm genes are marked examples. In vertebrates, alter-
native splicing of Tpms is a well-characterised process generating
many isoforms to carry out the protein’s different roles in muscle
contraction and in the function and structures of the actin cytoskel-
eton (Perry, 2001). There is evidence that this is also the case with
invertebrates and the current study conﬁrms that in S. mansoni, four
Tpm genes produce at least 13 splice variants.In vertebrates, different isoforms of Tpm are expressed in differ-
ent tissues and at different developmental stages (Perry, 2001). We
did not see tissue variations in SmTpm isoform proﬁles when for
example, comparing cercarial heads and tails, but there were some
differences in developmental expression across the life cycle. For
example, two of the isoforms were mutually exclusive. TpmII.2
was expressed only in the intermediate host and TpmII.5 only in
the deﬁnitive host. Interestingly, these isoforms are almost
identical except that different 30 exons generate entirely non-
homologous C-terminal domains (<15% identity). Most of the
SmTpm isoforms are, however, transcribed in all life stages, so
any differences in anti-isoform immune responses are unlikely to
be attributed to developmental expression patterns in the way
there have been with the SmTAL protein family (Fitzsimmons
et al., 2007, 2012a).
Whilst unable to measure the mRNA amounts of different splice
variants, we were able to show that overall expression of the TpmII
gene was by far the greatest in the adult parasite. Evidence from
vertebrate species would suggest that muscle and non-muscle iso-
forms have notable structural differences (Smillie, 1979; Côté,
Fig. 4. Puriﬁed recombinant Schistosoma mansoni tropomyosin (Tpm)II antigens. The four splice variants were expressed in Escherichia coli as GST fusion proteins, which were
then cleaved with thrombin and puriﬁed using glutathione-agarose chromatography. Shown are the thrombin digests (D) and puriﬁed TpmII proteins (P) separated on SDS–
PAGE. Tpm migrates anomalously in gel electrophoresis and the predicted and apparent (in parentheses) molecular weights are indicated .
Table 2
Circular dichroism analysis of puriﬁed Schistosoma mansoni tropomyosin (TpmII)
proteins.
TpmII isoforms Tma (C) % Alpha-helixb
(before heating)
% Alpha-helix
(after heating)
TpmII.3 52 100 100
TpmII.4 40 100 100
TpmII.7 38 100 90.9
TpmII.8 30 95.4 91.5
a Melting temperatures (Tm) were calculated by taking the maxima of the
derivatives of thermal denaturation curves. Normalised root-mean-squared S.D.
terms for all secondary structure determinations were <0.1.
b Percent helicity calculations were performed using the CONTINLL analysis
program and the SP175 190–240 nm reference data set on the Dichroweb interface.
Fig. 5. Circular dichroism (CD) spectra of helical Schistosoma mansoni tropomyosin
(Tpm)II splice variants. The UV CD spectra of TpmII.3, 4, 7 and 8 are shown before
thermal denaturation (solid lines) and after refolding by slow cooling (dashed
lines).
Fig. 6. Levels of IgE and IgG4 to Schistosoma mansoni tropomyosin (Tpm)II isoforms.
Levels of IgE (A) and IgG4 (B) to TpmII isoforms were measured in a population of
infected boys and men (n = 228) from an area endemic for S. mansoni, both before
and 7 weeks after treatment with Praziquantel. Shown are the levels (geometric
mean ± 95% conﬁdence interval) for those with a detectable response. The
prevalence (%) of each response (before treatment) in the cohort is indicated.
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whilst this is replaced in non-muscle isoforms, which tend to be
shorter overall. Mature schistosomes, especially the males, are
muscular creatures and muscle Tpm may be abundant. However
Fig. 7. Prevalence of anti-Schistosoma mansoni tropomyosin (Tpm)II IgE and IgG4 responses by age of participant. The pre-treatment prevalence data for the IgE and IgG4
responses to (A) TpmII.3, (B) TpmII.4, (C) TpmII.7 and (D) TpmII.8 are shown for ﬁve age groups: 7–9 years (n = 39), 10–14 years (n = 46), 15–25 years (n = 45), 26–36 years
(n = 50) and > 37 years (n = 48). The% of each group with a detectable response is plotted against the mean age of the group. Error bars represent 95% conﬁdence intervals.
Table 3
Age-adjusted linear regression model of participant re-infection with Schistosoma
mansoni 2 years post-treatment.
Parameter b (S.E.) P
Intercept 7.45 (1.631) <0.001
Age (versus 7–9 year age group) 10–14 yrs 0.034 (0.514) <0.001
15–25 yrs 0.747 (0.548)
26–36 yrs 2.073 (0.51)
37–76 yrs 2.548 (0.52)
Anti-SmTpmII.3 IgE levels 0.641 (0.326) 0.05
SmTpm, Schistosoma mansoni tropomyosin.
Table 4
Age-adjusted linear regression model of participant re-infection with Schistosoma
mansoni 2 years post-treatment.
Parameter b (S.E.) P
Intercept 4.626 (0.385) <0.001
Age (vs. 7–9 years) 10–14 yrs 0.021 (0.508) <0.001
15–25 yrs 1.01 (0.549)
26–36 yrs 2.403 (0.498)
37–76 yrs 2.49 (0.501)
Anti-SmTpmII.7 IgG4 levels 0.138 (0.049) 0.006
SmTpm, Schistosoma mansoni tropomyosin.
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Shore, 1990) indicate that most Tpm is non-muscle, found in other
parenchymal cells and in the tegument – the outer layer that
covers the muscle and acts as an interface with the host.
Some of the splice variants are very similar to each other (e.g.
TpmII.2 and TpmII.5 above). The swapping of a small number of
exons may make a functional difference to the protein but not
greatly inﬂuence antigenicity. For immunological study however,we chose four isoforms, TpmII.3, 4, 7 and 8, with marked regional
differences, especially in their N and C-terminal domains. TpmII.4
is a highly representative 284 residue, muscle-type isoform. It is
homologous to known Tpm allergens from shrimp (Pen a1) and
other invertebrates (Ayuso et al., 2002; Sereda et al., 2008), includ-
ing ﬁve sections of these molecules proposed to contain continu-
ous IgE epitopes (Sereda et al., 2008). Whilst SmTpmII.4 contains
sequences homologous to all ﬁve sections (Sereda et al., 2008),
TpmII.8 is truncated before the two C-terminal epitopes, and
TpmII.3 and TpmII.7 have entirely different N-terminal sections.
Moreover the unique N-terminal domains of TpmII.3 and TpmII.7
are likely to contain other epitopes speciﬁc for those isoforms.
Despite all the published data on continuous epitopes, it seems
that, in the major allergens at least, most IgE epitopes are of the
conformational (discontinuous) type (Arnon and Van Regenmortel,
1992; Valenta et al., 2004). Correct folding of antigens is therefore
crucially important and CD conﬁrmed that all the tested Tpm iso-
forms possessed the expected coiled-coil secondary and tertiary
structure. The native Tpm protein is a dimer of two Tpm chains,
which can associate end to end to form larger ﬁlamentous multi-
mers (Perry, 2001). Therefore it is possible that the quaternary
structure may generate further conformational epitopes. It is not
known whether these phenomena occur with the recombinant
SmTpm, but gel exclusion chromatography indicated that at least
one isoform, SmTpmII.4, formed large multimers in solution
(unpublished data).
Only a small number of protein families contain allergens/IgE-
antigens (Radauer, 2008) and Tpms represent some of the most
common (Reese et al., 1999). We believe this is the ﬁrst report of
an IgE response to schistosome Tpm. In this study IgE from infected
individuals bound to all four TpmII isotypes tested. Many individ-
uals also produced IgG4 that bound the four proteins. IgG4 is re-
garded as a blocking antibody, competing with IgE for antigen
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mediated activation of IgE-effector cells (Kepley et al., 2000; Smith
and Clatworthy, 2010). Whilst IgE has been associated with
resistance to re-infection, speciﬁc IgG4 responses, or rather high
IgG4:IgE ratios, have been correlated with susceptibility (Hagan
et al., 1991; Demeure et al., 1993; Li et al., 2001; Jiz et al., 2009;
Pinot de Moira et al., 2010).
There were signiﬁcant differences between the antibody
responses to the four different isoforms. Most striking was the dif-
ference between the two non-muscle molecules, TpmII.3 and
TpmII.7. The response to TpmII.3 was predominantly IgE, with
few people producing TpmII.3–IgG4. The response to TpmII.7 was
predominantly IgG4 with few individuals producing IgE. Given pre-
vious work linking the IgE:IgG4 balance to immunity, it is notable
that those with the IgE-dominated response to TmpII.3 were more
resistant to re-infection and those with the IgG4-dominated
response to TpmII.7 were more susceptible. The antibody re-
sponses to the muscle-type TpmII.4 and its truncated form,
TpmII.8, were very similar. They share many of the same epitopes,
have the same developmental expression pattern and if they are
both in the muscle, are likely to have a similar exposure pattern
to the host immune system. We have not established why the
two non-muscle forms evoke such different responses, although
they do have entirely different N-terminal domains and the rest
of the molecule is also relatively dissimilar. Nothing is known
about their tissue distribution or their accessibility to the host im-
mune system but these may be important factors in their
antigenicity.
Loverde and colleagues showed that individuals infected with S.
mansoni produced IgG against parasite Tpm (Xu et al., 1991) but
ours is the ﬁrst known report correlating the anti-Tpm response
with immunity. Invertebrate Tpm is a major clinical allergen,
shown to be targeted by human IgE in a number of helminth infec-
tions, now including schistosomes. Alternative splicing is an
important component of Tpm biology and this work shows it is a
key consideration in studying the IgE response to this allergenic
molecule.
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